Search
Ethinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnStructurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[A259736,A258488] The use of epcoritamab in this group of patients has high response rates, durable complete responses and manageable adverse events with few discontinuations. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial
Tigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalTigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. … It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Benazepril
go.drugbank.com/drugs/DB00542ApprovedInvestigationalBenazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. … Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigational[A7928] Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33359] Both drugs were inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>, but nirmatrelvir has the advantage of being orally bioavailable. … [L39544] It was fully approved by the FDA on May 25, 2023.
Almotriptan
go.drugbank.com/drugs/DB00918ApprovedIt works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedIt was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]